Toxicity‐dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials

Phase I trials of anti‐cancer therapies aim to identify a maximum tolerated dose (MTD), defined as the dose that causes unacceptable toxicity in a target proportion of patients. Both rule‐based and model‐based methods have been proposed for MTD recommendation. The escalation with overdose control (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheeler, Graham M., Sweeting, Michael J., Mander, Adrian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462100/
https://www.ncbi.nlm.nih.gov/pubmed/28295513
http://dx.doi.org/10.1002/sim.7280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462100/
https://www.ncbi.nlm.nih.gov/pubmed/28295513
http://dx.doi.org/10.1002/sim.7280

Ejemplares similares